Enoblituzumab

Enoblituzumab
Monoclonal antibody
Type	?
Source	Humanized (from mouse)
Target	B7-H3
Clinical data
Other names	MGA271
ATC code	none;
Identifiers
CAS Number	1353485-38-7;
ChemSpider	none;
UNII	M6030H73N9;
KEGG	D11752;
Chemical and physical data
Formula	C6474H9990N1726O2030S42
Molar mass	145829.71 g·mol−1

Enoblituzumab is a monoclonal antibody designed for the treatment of cancer.^[1] Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.

This drug was developed by MacroGenics, Inc.

References

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Enoblituzumab, American Medical Association.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Enoblituzumab, American Medical Association.

[1]